An International Randomized Study to Compare SPIES Versus WLI
Primary Purpose
Bladder Cancer
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SPIES+WLI assisted TURB
WLI assisted TURB
Sponsored by
About this trial
This is an interventional diagnostic trial for Bladder Cancer
Eligibility Criteria
Inclusion Criteria:
- Has signed informed consent
- Is scheduled for treatment of a primary or recurrent NMIBC
- Is aged 18 years or older
- Has or has had no tumors in the upper urinary tract
- Has had no previous irradiation of the pelvis
Exclusion Criteria:
- Gross haematuria at the time of TURB (i.e. heavy bladder bleeding resulting in marked amounts of blood in the urine which may interfere with cystoscopy)
- Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days
- Pregnancy or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and are suggested to use the contraceptive pill or an intrauterine device (IUD) during the treatments and for at least one months thereafter)
- Conditions associated with a risk of poor protocol compliance
- Has had instillation therapy in the six months prior to the screening visit
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
A
B
Arm Description
SPIES+WLI assisted TURB
WLI assisted TURB
Outcomes
Primary Outcome Measures
To compare the recurrence rate of tumor at 12 months following SPIES assisted TURB (Arm A) with White Light Imaging only assisted TURB (Arm B)
Secondary Outcome Measures
1. To assess the recurrence rate of tumor at short and long term follow up (3 months and 3 years) after SPIES or WLI assisted TURB in patients with NMIBC.
2. To assess the peri-operative morbidity (30 days) between SPIES and WLI assisted TURB by comparing the proportion of adverse events and using the Clavien-Dindo score.
Full Information
NCT ID
NCT02252549
First Posted
September 26, 2014
Last Updated
July 27, 2021
Sponsor
Clinical Research Office of the Endourological Society
1. Study Identification
Unique Protocol Identification Number
NCT02252549
Brief Title
An International Randomized Study to Compare SPIES Versus WLI
Official Title
The SPIES Non-Muscle-Invasive Bladder Cancer Study - A Multicenter Randomized Controlled Study; A Multicenter International Randomized Controlled Study to Compare the Outcome Using the Storz Professional Image Enhancement System (SPIES) Versus White Light Imaging (WLI) During TURB of Non-Muscle-Invasive Bladder Cancer (NMIBC).
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
April 2020 (Actual)
Study Completion Date
July 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinical Research Office of the Endourological Society
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is a multicenter randomized controlled trial in which the efficacy between SPIES assisted and WLI assisted TURB are compared. Subjects in the experimental arm (Arm A) will undergo SPIES assisted TURB, whereas subjects in the control arm (Arm B) will receive treatment with WLI assisted TURB only. Baseline characteristics will be recorded, as well as short and long-term follow up.
Detailed Description
This study is a multicenter randomized controlled trial in which the recurrence rates of cancer between SPIES assisted and WLI assisted TURB are compared. Randomization is stratified by tumor multiplicity (single or multiple), tumor status (primary or recurrent) and macroscopic findings (papillary or flat, where CIS is scored as flat lesion). Patients randomized into the experimental arm (Arm A) will undergo SPIES and WLI assisted TURB, whereas the patients in the control arm (Arm B) will undergo WLI only assisted TURB. WLI is chosen as control, since it is considered the gold standard for detecting bladder tumors. Short and long term follow up will be recorded in order to evaluate the health gains for patients over a longer period. Perioperative (30 days) complications will be compared between the two treatment arms to evaluate the safety of SPIES.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
700 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Active Comparator
Arm Description
SPIES+WLI assisted TURB
Arm Title
B
Arm Type
Active Comparator
Arm Description
WLI assisted TURB
Intervention Type
Device
Intervention Name(s)
SPIES+WLI assisted TURB
Intervention Type
Device
Intervention Name(s)
WLI assisted TURB
Primary Outcome Measure Information:
Title
To compare the recurrence rate of tumor at 12 months following SPIES assisted TURB (Arm A) with White Light Imaging only assisted TURB (Arm B)
Time Frame
1 year
Secondary Outcome Measure Information:
Title
1. To assess the recurrence rate of tumor at short and long term follow up (3 months and 3 years) after SPIES or WLI assisted TURB in patients with NMIBC.
Time Frame
3 years
Title
2. To assess the peri-operative morbidity (30 days) between SPIES and WLI assisted TURB by comparing the proportion of adverse events and using the Clavien-Dindo score.
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Has signed informed consent
Is scheduled for treatment of a primary or recurrent NMIBC
Is aged 18 years or older
Has or has had no tumors in the upper urinary tract
Has had no previous irradiation of the pelvis
Exclusion Criteria:
Gross haematuria at the time of TURB (i.e. heavy bladder bleeding resulting in marked amounts of blood in the urine which may interfere with cystoscopy)
Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days
Pregnancy or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and are suggested to use the contraceptive pill or an intrauterine device (IUD) during the treatments and for at least one months thereafter)
Conditions associated with a risk of poor protocol compliance
Has had instillation therapy in the six months prior to the screening visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean de la Rosette
Organizational Affiliation
Clinical Research Office of the Endourological Society
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
34741631
Citation
de la Rosette J, Martov A, Hurle R, Favre G, Mamoulakis C, Castanheira de Oliveira M, Stenzl A, Linares-Espinos E, Trelles Guzman CR, Gravas S, Knoll T, Boz MY, Herrmann T, Laguna P. Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results. World J Urol. 2022 Mar;40(3):727-738. doi: 10.1007/s00345-021-03866-4. Epub 2021 Nov 6.
Results Reference
derived
Learn more about this trial
An International Randomized Study to Compare SPIES Versus WLI
We'll reach out to this number within 24 hrs